https://pharmaceutical-journal.com/article/news/non-hormonal-treatment-for-menopause-vasomotor-symptoms-approved-for-use-in-the-uk
0
0
12/19/23 at 4:37pm
Organization
The Pharmaceutical Journal
Authors
The Medicines and Healthcare products Regulatory Agency (MHRA) has licensed fezolinetant (Veozah; Astellas Pharma) for the treatment of hot flushes in menopause. Fezolinetant is a neurokinin-3 receptor antagonist, which acts on the brain’s thermoregulatory ce…
Create an account
or login to join the discussion